Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Elevance Health Inc’s stock clocked out at $310.03, down -1.26% from its previous closing price of $314.0. In other words, the price has decreased by -$1.26 from its previous closing price. On the day, 1.84 million shares were traded. ELV stock price reached its highest trading level at $313.84 during the session, while it also had its lowest trading level at $307.6.
Ratios:
To gain a deeper understanding of ELV’s stock, we examine its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.69 whereas as Long-Term Debt/Eq ratio is at 0.64.
On July 18, 2025, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $310.
Robert W. Baird Downgraded its Outperform to Neutral on April 15, 2025, while the target price for the stock was maintained at $529.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 19 ’25 when DeVore Susan D. bought 1,200 shares for $312.15 per share. The transaction valued at 374,580 led to the insider holds 3,502 shares of the business.
BOUDREAUX GAIL bought 8,500 shares of ELV for $2,438,951 on Jul 18 ’25. The President and CEO now owns 151,020 shares after completing the transaction at $286.94 per share. On Apr 24 ’25, another insider, Kaye Mark, who serves as the EVP & CFO of the company, sold 4,588 shares for $424.82 each. As a result, the insider received 1,949,074 and left with 18,977 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELV now has a Market Capitalization of 69811937280 and an Enterprise Value of 65335029760. As of this moment, Elevance’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.20, and their Forward P/E ratio for the next fiscal year is 9.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.27. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.37 while its Price-to-Book (P/B) ratio in mrq is 1.59. Its current Enterprise Value per Revenue stands at 0.345 whereas that against EBITDA is 6.887.
Stock Price History:
The Beta on a monthly basis for ELV is 0.60, which has changed by -0.437424 over the last 52 weeks, in comparison to a change of 0.15624678 over the same period for the S&P500. Over the past 52 weeks, ELV has reached a high of $567.26, while it has fallen to a 52-week low of $273.71. The 50-Day Moving Average of the stock is -3.79%, while the 200-Day Moving Average is calculated to be -18.75%.
Shares Statistics:
It appears that ELV traded 2.38M shares on average per day over the past three months and 2296570 shares per day over the past ten days. A total of 224.84M shares are outstanding, with a floating share count of 224.71M. Insiders hold about 0.21% of the company’s shares, while institutions hold 92.65% stake in the company. Shares short for ELV as of 1755216000 were 3156964 with a Short Ratio of 1.19, compared to 1752537600 on 2719541. Therefore, it implies a Short% of Shares Outstanding of 3156964 and a Short% of Float of 1.39999995.
Dividends & Splits
With its trailing 12-month dividend rate of 6.68, ELV has a forward annual dividend rate of 6.68. Against a Trailing Annual Dividend Yield of 0.021273885The stock’s 5-year Average Dividend Yield is 1.22. The current Payout Ratio is 25.39% for ELV, which recently paid a dividend on 2025-06-10 with an ex-dividend date of 2025-09-10. Stock splits for the company last occurred on 2005-06-01 when the company split stock in a 2:1 ratio.
Earnings Estimates
The current rating of Elevance Health Inc (ELV) reflects the combined expertise of 16.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $4.11, with high estimates of $4.54 and low estimates of $1.96.
Analysts are recommending an EPS of between $32.15 and $28.77 for the fiscal current year, implying an average EPS of $30.02. EPS for the following year is $32.78, with 21.0 analysts recommending between $39.23 and $26.97.
Revenue Estimates
In the current quarter, 10 analysts expect revenue to total $49.22B. It ranges from a high estimate of $50.2B to a low estimate of $48.65B. As of the current estimate, Elevance Health Inc’s year-ago sales were $44.72BFor the next quarter, 10 analysts are estimating revenue of $49.36B. There is a high estimate of $50.9B for the next quarter, whereas the lowest estimate is $47.78B.
A total of 12 analysts have provided revenue estimates for ELV’s current fiscal year. The highest revenue estimate was $199.04B, while the lowest revenue estimate was $194.96B, resulting in an average revenue estimate of $196.92B. In the same quarter a year ago, actual revenue was $175.2BBased on 10 analysts’ estimates, the company’s revenue will be $208.37B in the next fiscal year. The high estimate is $213.85B and the low estimate is $200.55B.
